Take gene therapy, for example: the first one for spinal muscular atrophy (SMA), Zolgensma, was approved in the US in May 2019 and in Europe in ...
https://www.google.com/url?rct=j&sa=t&url=https://www.pharmatimes.com/magazine/2022/march_2022/single_dose_innovation&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNG1i-twa7GTjldNoNalD6RMdFk4PQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.